Emergent BioSolutions Reports Financial Results for Full Year 2010
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the full year ended December 31,...
Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced that a joint delegation of Members of the European Parliament (MEPs) and representatives from the Oxford-Emergent Tuberculosis Consortium (OETC) today...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10, 2011
Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for the fourth quarter and full year 2010 on Thursday, March 10, 2011, after market...
Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia
Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia...
Emergent BioSolutions Provides Preliminary 2010 Financial Results and Guidance for 2011
Emergent BioSolutions Inc. (NYSE: EBS) announced today preliminary, unaudited financial results for 2010 and guidance for...
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing...
Emergent BioSolutions to Webcast Presentation at JPMorgan Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the 29th Annual JPMorgan Healthcare Conference in San Francisco on Wednesday, January...
Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting
Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American...
Emergent BioSolutions Announces Acceptance of TRU-016 and TRU-Adhance Abstracts for Presentation at American Society of Hematology Meeting
Emergent BioSolutions Inc. (NYSE: EBS) today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology (ASH) to be held from...
Emergent BioSolutions Awarded Five Therapeutic Discovery Project Grants
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development...
Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the following investor conferences during the months of November and December...
Emergent BioSolutions Receives Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its fully human anthrax monoclonal antibody AVP-21D9, which is in development for the treatment of inhalation anthrax, has been granted...